EUVIMEDEUVIMED entdecken
Crossref

Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis

Yan Hu, Biao Yang, Chengju Xiao, Xinchun Yang, Hua Zhang, Pengbo Yang, Xiao Du, Guixiang Zhang, Beibei Liang, Nan Bai, Daoguang Zhang, Dongbo Wu und 25 weitere

Cell · 2026-04 · 189 (9) · 2663-2683.e26

DOI: 10.1016/j.cell.2026.02.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2026-04. Verfasst von Yan Hu und 36 weiteren Autor:innen. Beteiligte Einrichtung: Key Lab of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Respiratory Health and Multimorbidity, State Key …. Hauptthemen laut MEDLINE: rho-Associated Kinases, Liver Cirrhosis, Endothelial Cells. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 190 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a prominent pathological process contributing to death from hepatic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). There is limited treatment for liver fibrosis. Here, we find that upregulation of Rho-associated coiled-coil containing kinase 2 (ROCK2) in liver endothelial cells (ECs) and perivascular hepatic stellate cells (HSCs) causes vascular niche dysfunction and triggers pro-fibrotic angiocrine signaling. Based on the vascular druggable target ROCK2, we developed its selective inhibitor showing anti-fibrotic potency in preclinical models and human patients. The ROCK2-selective inhibitor TDI01 restored vascular phenotype and alleviated fibrosis in rodent and minipig MASH models. A phase 1 clinical trial (ChiCTR2200058868) of TDI01 demonstrated its favorable pharmacokinetics and safety in humans. An extended clinical trial (ChiCTR2400082056) showed a trend toward reducing liver fibrosis in five of six patients after TDI01 treatment. Thus, we discover vascular ROCK2 as a pro-fibrotic target, and development of an inhibitor selectively targeting angiocrine ROCK2 may provide a treatment of liver fibrosis in human patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesLiver CirrhosisEndothelial CellsAnimalsHumansHepatic Stellate CellsMaleLiverSwineMiceRatsFemaleProtein Kinase InhibitorsMice, Inbred C57BLSignal Transduction

Stichwörter der Autor:innen

MASHROCK2angiocrineclinical trialendothelial cellfenestrationhepatic stellate cellliver fibrosisliver regenerationvascular niche

Substanzen

rho-Associated KinasesROCK2 protein, humanRock2 protein, mouseProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Key Lab of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Respiratory Health and Multimorbidity, State Key Laboratory of Biotherapy, Division of Abdominal Tumor Multimodality Tr…
  • Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Beijing Tide Pharmaceutical Co., Ltd., Beijing 100176, China.
  • Center of Portal Hypertension, Zhongda Hospital, Southeast University, Nanjing 210009, China.
  • Faculty of Health Sciences, University of Macau, Macau SAR 999078, China.
  • Department of Neurology, The First Hospital of Jilin University, Changchun 130021, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., Zhang, D., Wu, D., Luo, Q., Teng, Y., Chen, Y., Guo, Z., Zhao, C., Ye, T., Chai, D., …, & Ding, B. S. (2026). Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis. Cell, 189(9), 2663-2683.e26. https://doi.org/10.1016/j.cell.2026.02.001

Vancouver

Hu Y, Yang B, Xiao C, Yang X, Zhang H, Yang P, et al. Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis. Cell. 2026;189(9):2663-2683.e26. doi:10.1016/j.cell.2026.02.001

BibTeX
@article{Hu2026,
  author = {Hu, Yan and Yang, Biao and Xiao, Chengju and Yang, Xinchun and Zhang, Hua and Yang, Pengbo and Du, Xiao and Zhang, Guixiang and Liang, Beibei and Bai, Nan and Zhang, Daoguang and Wu, Dongbo and Luo, Qinghua and Teng, Yangjing and Chen, Yumeng and Guo, Zhiqing and Zhao, Chengjian and Ye, Tinghong and Chai, Dong and Qi, Xiaolong and Zhong, Weiting and Chen, Jie and Dong, Haohao and Gao, Jinhang and He, Huanhuan and Chang, Junlei and Li, Xuri and Peng, Liang and Rafii, Shahin and Friedman, Scott L and Yi, Cheng and Cai, Yun and Zhao, Yanping and Wang, Hongjun and Wang, Chen and Cao, Zhongwei and Ding, Bi-Sen},
  title = {Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {9},
  pages = {2663--2683.e26},
  doi = {10.1016/j.cell.2026.02.001}
}
Kostenlos starten →